A new formulation of long-acting cabotegravir and alternative injection sites could potentially allow people to administer Cabenuva for HIV treatment or Apretude for pre-exposure prophylaxis (PrEP) at home. Currently, Cabenuva (cabotegravir and rilpivirine) is injected in the buttocks by a health care provider every month or every two months, while Apretude (cabotegravir alone) is given every other month. Scientists from ViiV Healthcare tested a high-concentration formulation of cabotegravir that contains twice as much active drug per volume, which reduces the size of the shots. In a study of HIV-negative volunteers, the experimental formulation injected into the butt, thigh or belly had similar safety and produced drug levels comparable to those of the current version. However, the drug didn’t last as long in the body, so monthly dosing would be necessary. Another study found that injecting cabotegravir and rilpivirine into the outer thigh muscle led to drug concentrations similar to those of buttocks injections, which could allow for self-administration.
Treatment: Self-Administration of Long-Acting Injectables
People could potentially administer Cabenuva for HIV treatment or Apretude for pre-exposure prophylaxis (PrEP) at home.